Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells Corrigendum in /mmr/13/1/1054

Xu,Dacai; Wang,Jianglin; Zhou,Zhenkang; He,Zhiwei; Zhao,Qing

doi:10.3892/mmr.2015.4477

Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells

Corrigendum in: /mmr/13/1/1054

Authors:
- Dacai Xu
- Jianglin Wang
- Zhenkang Zhou
- Zhiwei He
- Qing Zhao
View Affiliations

Affiliations: Department of Biochemistry, Guangzhou Medical University, Guangzhou, Guangdong 510182, P.R. China, School of Mathematics, South China University of Technology, Guangzhou, Guangdong 510640, P.R. China, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan, Guangdong 523376, P.R. China
Published online on: October 23, 2015 https://doi.org/10.3892/mmr.2015.4477
Pages: 7963-7970
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the leading cause of cancer-associated mortality worldwide; however, only limited therapeutic treatments are currently available. The present study aimed to investigate the effects of cannabinoids as novel therapeutic targets in HCC. In addition, the mechanism underlying the effects of a synthetic cannabinoid, WIN55, 212‑2, on the BEL7402 HCC cell line was investigated. The results demonstrated that WIN55, 212‑2 induced cell cycle arrest of the BEL7402 cells at the G0/G1 phase via cannabinoid receptor 2 (CB2)‑mediated downregulation of phosphorylated-extracellular signal-regulated kinases (ERK)1/2, upregulation of p27, and downregulation of cyclin D1 and cyclin‑dependent kinase 4. Furthermore, inhibition of CB2 with the CB2 antagonist AM630 abrogated WIN55, 212‑2‑induced cell cycle arrest. Inhibition of ERK1/2 also resulted in cell cycle dysregulation and cell cycle arrest at the G0/G1 phase, which subsequently resulted in cell growth inhibition. In addition, the present study detected a significant reduction in matrix metalloproteinase‑9, retinoblastoma protein and E2F1 expression, and migration inhibition by WIN treatment. These results suggested that cannabinoid receptor agonists, including WIN, may be considered as novel therapeutics for the treatment of HCC.

View Figures

View References

1	Lin H, van den Esschert J, Liu C and van Gulik TM: Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 26:28–35. 2011. View Article : Google Scholar
2	Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL and Inoue M: Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures. J Epidemiol. 21:401–416. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sia D and Villanueva A: Signaling pathways in hepatocellular carcinoma. Oncology. 81(Suppl 1): 18–23. 2011. View Article : Google Scholar
4	Qin LX: Recent progress in predictive biomarkers for metastatic reccurrence of human hepatocellular carcinoma: A review of the literature. J Cancer Res Clin Oncol. 130:497–513. 2004. View Article : Google Scholar : PubMed/NCBI
5	Tabrizian P, Franssen B, Jibara G, Sweeney R, Sarpel U, Schwartz M and Labow D: Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. J Surg Oncol. 110:786–790. 2014. View Article : Google Scholar : PubMed/NCBI
6	Hermanson DJ and Marnett LJ: Cannabinoids, endocan-nabinoids, and cancer. Cancer Metastasis Rev. 30:599–612. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bowles DW, O'Bryant CL, Camidge DR and Jimeno A: The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol. 83:1–10. 2012. View Article : Google Scholar
8	Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, Vento R and Tesoriere G: Apoptosis induced in HepG2 cells by the synthentic cannabinoid WIN: Involvement of the transcription factor PPARgamma. Biochimie. 91:457–465. 2009. View Article : Google Scholar
9	Calvaruso G, Pellerito O, Notaro A and Giuliano M: Cannabinoid-associated cell death mechanisms in tumor models (review). Int J Oncol. 41:407–413. 2012.PubMed/NCBI
10	Chakravarti B, Ravi J and Ganju RK: Cannabinoids as therapeutic agents in cancer: Current status and future implications. Oncotarget. 5:5852–5872. 2014. View Article : Google Scholar : PubMed/NCBI
11	Sarfaraz S, Afaq F, Adhami VM, Malik A and Mukhtar H: Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem. 281:39480–39491. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hong Y, Zhou Y, Wang Y, Xiao S, Liao DJ and Zhao Q: PPARγ mediates the effects of WIN55,212-2, an synthetic cannabinoid, on the proliferation and apoptosis of the BEL-7402 hepatocarcinoma cells. Mol Biol Rep. 40:6287–6293. 2013. View Article : Google Scholar : PubMed/NCBI
13	Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE and Ganju RK: Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila). 4:65–75. 2011. View Article : Google Scholar
14	Xian XS, Park H, Choi MG and Park JM: Cannabinoid receptor agonist as an alternative drug in 5-fuorouracil-resistant gastric cancer cells. Anticancer Res. 33:2541–2547. 2013.PubMed/NCBI
15	Brandi J, Dando I, Palmieri M, Donadelli M and Cecconi D: Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists. Electrophoresis. 34:1359–1368. 2013. View Article : Google Scholar : PubMed/NCBI
16	Dainese E, Oddi S, Bari M and Maccarrone M: Modulation of the endocannabinoid system by lipid rafts. Curr Med Chem. 14:2702–2715. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zeni O, Sannino A, Romeo S, Micciulla F, Bellucci S and Scarf MR: Growth inhibition, cell-cycle alteration and apoptosis in stimulated human peripheral blood lymphocytes by multi-walled carbon nanotube buckypaper. Nanomedicine (Lond). 10:351–360. 2015. View Article : Google Scholar
18	Sánchez I and Dynlacht BD: New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol. 16:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kumar P and Wood C: Kaposi's sarcoma-associated herpesvirus transactivator Rta induces cell cycle arrest in G0/G1 phase by stabilizing and promoting nuclear localization of p27kip. J Virol. 87:13226–13238. 2013. View Article : Google Scholar : PubMed/NCBI
20	Deshpande A, Sicinski P and Hinds PW: Cyclins and cdks in development and cancer: A perspective. Oncogene. 24:2909–2915. 2005. View Article : Google Scholar : PubMed/NCBI
21	Ma X, Gao Y, Fan Y, Ni D, Zhang Y, Chen W, Zhang P, Song E, Huang Q, Ai Q, et al: Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma. PLoS One. 8:e734362013. View Article : Google Scholar : PubMed/NCBI
22	Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ and Chellappan SP: Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res. 72:516–526. 2012. View Article : Google Scholar :
23	Pillai S, Kovacs M and Chellappan S: Regulation of vascular endothelial growth factor receptors by Rb and E2F1: Role of acetylation. Cancer Res. 70:4931–4940. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lukaszewicz-Zając M, Mroczko B and Szmitkowski M: Gastric cancer - The role of matrix metalloproteinases in tumor progression. Clin Chim Acta. 412:1725–1730. 2011. View Article : Google Scholar